Salem Radio Network News Tuesday, June 19, 2018

Health

FDA finds deficiencies in Mylan’s generic Advair

(Reuters) – U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline’s blockbuster inhaled lung drug, Advair, and cited “minor deficiencies” with the copycat version.

Mylan said http://newsroom.mylan.com/press-releases?item=123580 it expects to receive a formal complete response letter from the U.S. Food And Drug Administration on June 27 and would determine what impact, if any, it would have on its full-year forecast.

The company’s shares fell 4 percent to $40.00 after the bell.

(Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

Previous
Next
AdvertisementAdvertise with Us
Advertisement
Advertisement

Editorial Cartoons

View More » 1529004642762551jzfaVFQYJK

Michael Ramirez
Wed, Jun 13, 2018

Advertisement
Advertisement
Advertisement
X CLOSE